Shots:

• The CHMP has granted positive opinion to the company’s fruquintinib (VEGFR-1, -2 & -3 inhibitor) for previously treated metastatic colorectal cancer (mCRC) adults. Takeda holds its global license outside of mainland China, Hong Kong & Macau while HUTCHMED has commercialization rights across China
• The opinion was based on P-III (FRESCO-2) study assessing fruquintinib + best supportive care (BSC) vs PBO in previously treated mCRC patients
• The study met the 1EPs and 2EPs demonstrating improved OS & PFS with consistent benefits in patients irrespective of previous treatment plus favourable safety profile. The data was published in The Lancet

Ref: Takeda | Image: Takeda

Related News:- The NMPA Accepts HUTCHMED and Innovent’s NDA for Fruquintinib Plus Sintilimab with Priority Review to Treat Endometrial Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com